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Transcription factors have proven to be difficult targets for the development of small-molecule drugs. In this
issue ofCancer Cell, Cerchietti et al. identify and characterize a specific, small-molecule inhibitor of BCL6, an
oncogenic transcriptional repressor, that has high clinical promise for treating diffuse large B cell lymphoma.Personalized cancer medicine offers the
hope that by identifying cancer-causing
mutations in critical regulatory genes,
we can target these mutant proteins to
cure cancer while limiting the side ef-
fects. A major roadblock to this has been
our inability to find specific, bioavailable
small-molecule inhibitors of nonenzy-
matic proteins, especially transcription
factors (Arkin and Wells, 2004). Enzymes
have been amenable therapeutic targets
because active sites have a structural
topology conducive to specific inhibition
by small molecules (Arkin and Whitty,
2009) and as a result many currently
available drugs target enzymes. Although
these drugs have proven effective, little
progress has been made toward identi-
fying inhibitors of oncogenic transcription
factors. In this issue of Cancer Cell, Cer-
chietti et al. provide a roadmap to circum-
vent this roadblock for the most common
form of diffuse large B cell lymphoma
(DLBCL) by identifying a specific small-
molecule inhibitor of BCL6, an oncogenic
transcriptional repressor that is respon-
sible for the majority (40%–70%) of this
malignancy (Cerchietti et al., 2010).
During the rapid expansion of activated
B cells in germinal centers of lymphoid
tissues, immunoglobulin gene loci under-
go recombinations and somatic hyper-
mutations in order to generate diversity
in antibodies against various foreign anti-
gens (Jardin et al., 2007; Lossos, 2005;
Parekh et al., 2008). Germinal center B
cells rapidly proliferate despite a state of
physiologic genomic instability because
BCL6 represses a cadre of genes involved
in regulation of theDNAdamage responseand cell cycle checkpoints, such as ATR,
CHK1, TP53, and CDKN1A (Figure 1A).
After clonal diversity has been accom-
plished, BCL6 is downregulated at the
mRNA and protein levels. Suppression of
BCL6 allows engagement of cell cycle
checkpoints and further B cell differentia-
tion and maturation. Oncogenic overex-
pression of BCL6, whether via chromo-
somal translocation, promoter mutation,
or gene amplification, permits continued
B progenitor cell proliferation and acquisi-
tion of additional mutations. Not surpris-
ingly, this leads to the formation of an
aggressive B cell lymphoma.
Cerchietti et al. used structural analysis
of BCL6 and indentified a pocket within
the BTB repression domain that is
required for recruitment of theSMRTcore-
pressor that links BCL6 to histone deace-
tylases to repress transcription. Computer
modeling allowed the identification of a
set of 1000 small molecules predicted to
bind the target pocket. These compounds
were organized by structural similarity into
100 groups and one to two compounds
were selected for further study from each
groupbasedon favorable drugproperties.
Of the nearly 200 compounds selected,
100 were commercially available, circum-
venting the need for chemical synthesis,
which iscostlyand timeconsuming. These
100 compounds were then screened for
their ability to block BCL6-mediated tran-
scriptional repression. From successive
rounds of screening a lead compound,
‘‘79-6,’’ with favorable chemical composi-
tion emerged that reproducibly inhibited
BCL6. Compound 79-6 bound the target
pocket of the BTB domain of BCL6 andCancer Celprevented the recruitment of corepressor
complexes to the ATR locus without
affecting BCL6 binding to the DNA. 79-6
appears to selectively inhibit BCL6
because it did not affect transcription
repression caused by several other BTB-
containing proteins. The addition of 79-6
to DLBCL cell lines reactivated BCL6-
regulated genes only in DLBCLs express-
ing BCL6, but had no effect on DLBCL
lines that did not express BCL-6. This
effect translated into 79-6 specifically
inducing apoptosis in BCL6-dependent
DLBCLs transplanted into SCID mice,
but not in BCL6-independent tumors. As
hoped fora targeted therapeuticdrug,only
minor toxicities (mild leucopenia) were
identified in mice administered many
rounds of drug.
This work represents one of the few true
examples of ‘‘transcriptional therapy.’’
Although histone deacetylase inhibitors
and DNA methyltransferase inhibitors
have traditionallybeen thoughtofasacting
through altering transcription, it has been
difficult to pin downacommonly regulated
target (or even a pathway) that would
explain the ability of these drugs to affect
a wide variety of tumor types. Therefore,
it is possible that these epigenetic regula-
tors, perhaps through chromatin effects,
cause problems with DNA replication or
repair, that kills rapidly cycling tumor cells
(Stimson et al., 2009). By contrast, 79-6
specifically targets the recruitment of
corepressors and HDACs to allow the
expression of key regulatory factors that
engage checkpoints and kill DLBCLs.
This type of targeted transcriptional inhibi-
tion, via structures to fit small moleculesl 17, April 13, 2010 ª2010 Elsevier Inc. 315
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Figure 1. Schematic Model of How the BCL6 Inhibitor 79-6 Blocks Transcriptional
Repression by BCL6
(A) BCL6 binds to its target loci (yellow line) and recruits SMRT and histone deacetylase 3 (HDAC3) that
mediate transcriptional repression. As a result, the expression of key regulators of the DNA damage
response and checkpoint activation, such as ATR, CHK1, TP53, and CDK1NA, is repressed. This allows
for rapid B cell proliferation in germinal centers during a state of physiologic genomic instability necessary
for recombination and somatic hypermutation of immunoglobulin loci. Oncogenic overexpression of BCL6
permits continued B cell proliferation and accumulation of DNA damage leading to formation of DLBCL.
(B) A small-molecule inhibitor of BCL6 identified by Chercietti et al. (depicted by purple ovals) blocks
recruitment of corepressor complexes to BCL6 target genes. The resulting expression of DNA damage
response proteins and checkpoint regulators promotes cell cycle arrest and apoptosis in DLBCLs. This
approach may be especially useful in conjunction with rituximab, an anti-CD20 monoclonal antibody.
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other high-value cancer targets might be
attacked, even old standards such as
c-Myc that have failed high-throughput
screening methods.
One of the remarkable characteristics
of 79-6 is its specificity for BCL6 over
highly related BTB domain-containing
factors. By comparison, tyrosine kinase
inhibitors that have had great success in
chronicmyelogenous leukemia (CML) and
efficacy in solid tumors (e.g., lung, breast)
are ATP analogs that affect multiple
kinases. Given that kinase signaling cas-
cades ultimately affect transcription
factors that control many genes, kinase
inhibitors that are commonly thought to
be targeted therapeutics probably have
far more wide-ranging effects than would
a compound such as 79-6.
Chemotherapy and radiation are the
mainstay therapies for many types of
cancer, including DLBCLs. The regimen316 Cancer Cell 17, April 13, 2010 ª2010 Elsfor DLBCL includes cyclophosphomide,
doxorubicin, vincristine, and prednisone
with the recent addition of rituximab
(R-CHOP therapy) (Kahl, 2008). Alkylating
agents and topoisomerase inhibitors,
such as cyclophosphamide and doxoru-
bricin, respectively, induce DNA damage
whereas vincristine inhibits microtubule
functions essential for mitosis. These
drugs all target rapidly cycling cells and
thus have numerous toxic side affects.
Rituximab is a monoclonal antibody
against CD20, a B cell-selective antigen,
which elicits complement-mediated B cell
destruction (Figure 1B). Given that BCL6
recruits corepression complexes con-
taining HDAC3, HDAC inhibitors have
been applied to DLBCL in clinical trials.
However, these agents have been largely
disappointing as single-agent therapies
in phase II trials. This may be due to the
nonselective action of the agents used
to date that inhibit multiple HDACs, andevier Inc.more selective inhibitors (e.g., HDAC3
inhibitors; Figure 1A) may be more useful.
However, as our ability to identify BCL6-
overexpressing lymphomas is refined, the
personalized approach of using a very
selective BCL6 inhibitor in combination
with a second, highly selective agent such
as rituximab may be very effective with
only limited side effects (Figure 1B).
We have gained significant insight into
the genes, molecules, and pathways that
cause or contribute to the pathogenesis
of many diseases. Although this has led
to more informed selection of therapeutic
targets for drug development, the iden-
tification of therapeutic compounds with
biologic specificity, adequate bioavail-
ability, and favorable pharmacokinetics
remains an enormous challenge. Cher-
chietti et al. have provided an eloquent
example of investigators collaborating
to meet this challenge. As more cancer
genomes are sequenced and the price of
a human genome approaches afford-
ability, additional inhibitors, similar to 79-
6,will be needed to attack the tremendous
genetic diversity that underlies tumor
development and win the war against
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